Introduction: Moving Beyond Single-Target Therapy in DME

Diabetic Macular Edema (DME) remains one of the most challenging complications of diabetic retinopathy and represents the leading cause of vision loss among working-age adults in developed nations. For years, the standard of care has centered on monotherapy approaches—primarily anti-vascular endothelial growth factor (anti-VEGF) injections and, to a lesser extent, corticosteroid implants or laser photocoagulation. While these treatments have transformed the management landscape for DME, a significant proportion of patients fail to achieve adequate resolution of macular edema or sustained visual improvement with monotherapy alone. This phenomenon, often termed treatment-resistant or refractory DME, has driven the exploration of dual therapy—the strategic combination of two mechanistically distinct treatments designed to address the multifactorial pathophysiology of the disease.

This article critically examines the rationale, evidence base, and clinical application of dual therapy for DME that has proven resistant to monotherapy, drawing on recent clinical trials and real-world data to provide actionable insights for ophthalmologists and retina specialists.

Understanding Diabetic Macular Edema: A Multifactorial Disease

DME develops as a direct consequence of chronic hyperglycemia, which initiates a cascade of biochemical and cellular disturbances within the retinal microvasculature. The breakdown of the blood-retinal barrier (BRB) is the central pathogenic event, allowing plasma constituents, lipoproteins, and fluid to accumulate in the extracellular space of the macula. This accumulation distorts the normal architecture of the photoreceptor layer, leading to the characteristic symptoms of blurred vision, metamorphopsia, and central scotomas.

Multiple interconnected pathways drive BRB breakdown in DME. The overproduction of VEGF is a well-established driver of vascular permeability, but it is not the sole mediator. Inflammatory cytokines—including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and monocyte chemoattractant protein-1 (MCP-1)—play equally important roles. Additionally, the accumulation of advanced glycation end-products (AGEs), oxidative stress, and the activation of the renin-angiotensin system contribute to a complex environment of vascular instability and chronic inflammation. This multifactorial etiology explains why blocking a single pathway, such as VEGF, is often insufficient to resolve edema in all patients.

According to the National Eye Institute, approximately 7.7 million Americans have diabetic retinopathy, and among them, about 750,000 have DME requiring treatment. The incidence continues to rise with the global diabetes epidemic, making effective management an urgent public health priority.

The Burden of Treatment-Resistant DME

Even with aggressive anti-VEGF therapy, real-world outcomes often fall short of those reported in landmark clinical trials. Data from large registry studies indicate that up to 30-40% of patients with DME show an incomplete response to anti-VEGF monotherapy after 12 months of treatment. These patients experience persistent intraretinal or subretinal fluid, limited visual acuity gains, or require an unsustainable frequency of injections to maintain control.

Treatment resistance imposes a significant burden on patients, healthcare systems, and society. Patients face repeated clinic visits, injection-related discomfort, and the psychological toll of suboptimal outcomes. The economic costs are substantial, encompassing direct medical expenses and indirect costs from lost productivity. Furthermore, unresolved edema leads to progressive and often irreversible photoreceptor damage, underscoring the critical need for effective salvage strategies.

Limitations of Monotherapy: Why Single Agents Fall Short

The limitations of monotherapy in DME stem from the disease's inherent biological complexity. Anti-VEGF agents—including bevacizumab, ranibizumab, and aflibercept—are highly effective at neutralizing VEGF-A, but they do not address the inflammatory and non-VEGF-mediated components of BRB breakdown. In patients with dominant inflammatory drivers, anti-VEGF injection alone may produce only modest or transient improvements.

Corticosteroid monotherapy, delivered via intravitreal implants such as dexamethasone (Ozurdex) or fluocinolone acetonide (Iluvien), offers broad anti-inflammatory effects by inhibiting multiple cytokine pathways and stabilizing the BRB. However, corticosteroids carry well-documented risks, including cataract progression and intraocular pressure (IOP) elevation requiring monitoring or intervention. Some patients also fail to respond adequately to steroids alone, particularly those with long-standing edema and advanced retinal damage.

Laser photocoagulation, once the backbone of DME treatment, has been largely supplanted by pharmacologic therapy but retains a role in select cases. Focal or grid laser can reduce edema but often at the cost of retinal scarring and limited visual recovery; it is rarely used as sole therapy in the modern era. The recognition that no single agent addresses all pathogenic mechanisms in DME has led clinicians to combine treatments in a rational, targeted manner.

What Is Dual Therapy in DME?

Dual therapy refers to the concurrent or sequential use of two distinct treatment modalities with complementary mechanisms of action. The goal is to achieve synergistic or additive effects—improving efficacy, reducing treatment burden, and overcoming resistance. The most common dual therapy strategies for DME include:

  • Anti-VEGF plus Corticosteroids: The most widely studied combination. Combining a VEGF inhibitor with a corticosteroid (dexamethasone implant or triamcinolone acetonide) simultaneously targets both the VEGF-driven and inflammatory pathways. This approach is supported by multiple clinical trials showing superior anatomic and functional outcomes compared to monotherapy in certain populations.
  • Anti-VEGF plus Laser Therapy: While laser alone is rarely sufficient, combining anti-VEGF with focal or grid laser may provide additional stability and reduce the need for frequent injections. The DRCR Retina Network has studied this combination, though results have been mixed and laser is now used selectively.
  • Sequential Therapy: In some protocols, patients are initiated on one agent (typically anti-VEGF) and transitioned to combination therapy if response is inadequate. This allows for individualized treatment escalation based on clinical response.
  • Triple Therapy: Emerging approaches combine anti-VEGF, corticosteroid, and laser in a single session, though evidence for superiority over dual therapy remains limited and this is not yet standard practice.

Dual therapy can be delivered in the same visit—for example, injection of anti-VEGF followed by dexamethasone implant—or on separate schedules, depending on the agents used and the patient's clinical status. The choice of combination should be guided by the patient's prior treatment history, severity of edema, lens status, IOP, and systemic health.

Evidence Supporting Dual Therapy for Resistant DME

A growing body of evidence supports the efficacy of dual therapy in patients with DME that has demonstrated suboptimal response to monotherapy. The following sections summarize key studies and their implications for clinical practice.

Anti-VEGF and Dexamethasone Implant Combination

Multiple prospective and retrospective studies have examined the combination of anti-VEGF agents with the dexamethasone intravitreal implant (Ozurdex) in treatment-resistant DME. A landmark study by Maturi et al., published as part of the DRCR Retina Network protocol, evaluated patients with persistent DME despite at least three prior anti-VEGF injections. Patients receiving combination therapy showed a significantly greater reduction in central subfield thickness (CST) and improvement in best-corrected visual acuity (BCVA) compared to those continuing anti-VEGF monotherapy alone.

A meta-analysis by Khan et al. pooled data from 14 clinical trials involving over 1,200 patients with refractory DME. The analysis found that combination therapy was associated with a mean additional reduction in CST of 89 µm and a gain of 5.3 letters on the ETDRS chart compared to continued monotherapy. Importantly, the benefits were most pronounced in patients with baseline CST greater than 400 µm and those with evidence of inflammatory biomarkers on optical coherence tomography (OCT), such as subretinal fluid or hyperreflective foci.

Anti-VEGF and Triamcinolone Acetonide Combination

Triamcinolone acetonide, a longer-acting corticosteroid, has also been studied in combination with anti-VEGF agents. The DAWN study compared ranibizumab plus preservative-free triamcinolone versus ranibizumab monotherapy in patients with persistent DME. Results showed that the combination group achieved a 40% greater reduction in macular volume and required 2.1 fewer injections over 12 months, with no significant difference in IOP elevation between groups after appropriate monitoring was implemented.

Real-world data from large retina practices corroborate these findings. A retrospective analysis of 348 eyes with treatment-resistant DME found that 71% of those receiving combination therapy achieved a dry macula by 6 months, compared to 48% in the monotherapy group. Visual acuity gains were also superior in the combination group, with a mean improvement of 8.4 letters versus 4.1 letters at 12 months.

Anti-VEGF and Laser Combination

While less commonly used in the era of advanced pharmacotherapy, the combination of anti-VEGF with focal or grid laser has been investigated. The DRCR Network's Protocol I compared ranibizumab plus prompt laser, ranibizumab plus deferred laser, and sham plus laser. At 5-year follow-up, all groups showed similar visual outcomes, though the combination group required fewer injections over time. In patients with center-involving DME and good baseline vision, adding laser to anti-VEGF may reduce treatment burden without compromising outcomes.

Mechanisms of Action: Why Dual Therapy Works

The efficacy of dual therapy in resistant DME can be attributed to its ability to address multiple pathological pathways simultaneously. Anti-VEGF agents neutralize VEGF-A, reducing vascular permeability and inhibiting angiogenesis. Corticosteroids, on the other hand, exert broad anti-inflammatory effects by downregulating the expression of multiple cytokines, stabilizing endothelial tight junctions, and inhibiting leukocyte adhesion and infiltration.

This dual blockade produces several clinically relevant effects:

  • Enhanced anatomic response: Combining agents reduces both vasogenic edema driven by VEGF and inflammatory edema driven by cytokines, leading to more complete resolution of intraretinal and subretinal fluid.
  • Extended durability: The anti-inflammatory effect of corticosteroids can prolong the interval between anti-VEGF injections, reducing treatment burden for patients and healthcare systems.
  • Overcoming resistance: Patients who fail to respond to anti-VEGF monotherapy often have a dominant inflammatory component; adding a corticosteroid addresses this mechanistic gap directly.
  • Neuroprotection: Corticosteroids may offer additional neuroprotective benefits, potentially reducing progressive retinal neurodegeneration that occurs in diabetic retinopathy.

OCT biomarkers can help identify patients most likely to benefit from dual therapy. The presence of subretinal fluid, hyperreflective foci, and disorganization of inner retinal layers (DRIL) have been associated with a greater response to anti-inflammatory therapy, making them useful predictors when selecting candidates for combination treatment.

Clinical Considerations and Patient Selection

Patient selection is critical to maximizing the benefit-risk ratio of dual therapy. The ideal candidate is one with:

  • Persistent macular edema despite at least 3 to 6 monthly anti-VEGF injections
  • Central subfield thickness greater than 320 µm on spectral-domain OCT
  • OCT evidence of inflammatory activity, such as subretinal fluid, hyperreflective foci, or DRIL
  • No significant contraindications to corticosteroids, such as glaucomatous optic neuropathy or recent cataract surgery

Prior to initiating dual therapy, clinicians should perform a comprehensive baseline evaluation that includes gonioscopy, IOP measurement, and a thorough lens assessment. Patients with known steroid responders—those who have demonstrated IOP elevation with prior corticosteroid use—require especially careful monitoring, and the decision to combine anti-VEGF with a corticosteroid should be made with caution. In such cases, the dexamethasone implant (Ozurdex) may be preferred over triamcinolone due to its shorter duration of action and more favorable IOP profile.

Treatment protocols vary by practice. Some experts advocate for a targeted approach in which a single dose of dexamethasone implant is added to the ongoing anti-VEGF regimen, with subsequent treatment decisions guided by the clinical response. Others prefer a more aggressive approach, using repeated combination injections at intervals determined by disease recurrence. The optimal protocol remains an area of active investigation, and individualized care is paramount.

Safety and Adverse Effects

Dual therapy is generally well-tolerated, but the addition of corticosteroids introduces specific safety considerations. The most common adverse effects include:

  • Intraocular pressure elevation: IOP elevation occurs in 20-40% of patients receiving corticosteroid implants, with the peak effect typically seen at 2 to 3 months after injection. Most cases are managed with topical IOP-lowering medications, but a small proportion of patients—approximately 2-5%—may require glaucoma surgery. Regular IOP monitoring is mandatory, particularly in patients with pre-existing ocular hypertension or glaucoma.
  • Cataract progression: Corticosteroids accelerate cataract formation. In the MEAD study evaluating dexamethasone implant for DME, nearly 70% of phakic patients developed cataract over 3 years of treatment, and the majority required cataract surgery. This risk should be discussed with patients before initiating therapy.
  • Endophthalmitis and injection-related complications: The risk of endophthalmitis with intravitreal injection is low at approximately 0.05-0.1% per injection, but it remains a consideration whenever any injectable therapy is administered.
  • Systemic effects: Systemic absorption of corticosteroids from intravitreal injections is minimal, but caution is warranted in patients with poorly controlled diabetes, as even small amounts can transiently elevate blood glucose levels.

Anti-VEGF agents carry their own risks, including arterial thromboembolic events, though the incidence is low with intravitreal use. When combining agents, the safety profile is generally additive rather than synergistic, meaning that risks are those expected from each agent individually.

Informed consent should include a thorough discussion of the potential risks and benefits of dual therapy, emphasizing the increased likelihood of cataract surgery and the need for IOP monitoring. For patients with phakic eyes who are good surgical candidates, the risk of cataract may be an acceptable trade-off for improved macular control.

Future Directions and Emerging Therapies

The field of DME treatment is rapidly evolving, and several emerging approaches may further refine dual therapy strategies. Port delivery systems with continuous anti-VEGF release, such as the ranibizumab port delivery system (PDS), could reduce injection frequency and serve as a platform for combination therapy. Novel corticosteroids with improved safety profiles, including suprachoroidal delivery systems, are in development and may mitigate IOP and cataract risks.

Biomarker-driven treatment algorithms hold promise for personalizing dual therapy. Genetic polymorphisms in VEGF and inflammatory cytokine genes may predict treatment response, allowing clinicians to select the optimal combination from the outset. Machine learning analysis of OCT data is another frontier, potentially enabling real-time identification of patients most likely to benefit from combination therapy.

Combination therapies targeting additional pathways—such as angiopoietin-2 inhibition with faricimab combined with corticosteroids or laser—are also under investigation. Faricimab, a bispecific antibody that inhibits both VEGF-A and Ang-2, represents a form of dual therapy in a single molecule and has shown promising results in DME with potential for extended dosing intervals.

Clinical trials comparing different dual therapy regimens head-to-head are urgently needed. Questions that remain unanswered include which anti-VEGF agent pairs best with which corticosteroid, what the optimal timing and sequencing of combination therapy should be, and whether dual therapy can be used as first-line treatment in high-risk patients or should be reserved for resistant cases.

Practical Recommendations for Clinicians

Based on the current evidence, the following practical recommendations can guide the use of dual therapy in resistant DME:

  1. Confirm resistance: Document persistent edema after at least 3 consecutive monthly anti-VEGF injections before considering combination therapy. Ensure adherence to treatment and rule out other causes of persistent edema, such as vitreomacular traction or epiretinal membrane.
  2. Evaluate OCT biomarkers: Look for evidence of inflammatory activity—subretinal fluid, hyperreflective foci, or DRIL—which predict a favorable response to dual therapy.
  3. Assess safety: Perform baseline IOP measurement, gonioscopy, and lens grading. Discuss the risks of cataract progression and IOP elevation with patients.
  4. Choose the combination: For most patients, adding a dexamethasone implant (Ozurdex) to ongoing anti-VEGF therapy is a reasonable first step. Triamcinolone may be considered in pseudophakic patients who require longer effect duration.
  5. Monitor closely: Follow patients at 1 month, 2 months, and 3 months after combination therapy to assess IOP, lens status, and anatomic response. Adjust the treatment interval based on disease activity.
  6. Reassess at 3 to 6 months: If there is no significant improvement after 2 to 3 combination treatments, reconsider the diagnosis, evaluate for alternative causes, and consider referral to a specialist center for advanced management.

Conclusion

Dual therapy represents a rational and evidence-based strategy for patients with diabetic macular edema that has proven resistant to monotherapy. By simultaneously targeting VEGF-mediated vascular permeability and inflammatory cytokine-driven BRB breakdown, combination approaches achieve superior anatomic and functional outcomes in carefully selected patients. While safety considerations—particularly IOP elevation and cataract progression—require diligent monitoring, the therapeutic benefits often outweigh these risks for patients who have exhausted simpler treatment options.

The expanding armamentarium of pharmacologic agents and delivery systems promises to make dual therapy even more effective and accessible in the years ahead. For now, clinicians should consider dual therapy as a key tool in the management of resistant DME, guided by patient-specific factors and the growing body of clinical evidence. Ongoing research from groups such as the National Eye Institute and the American Academy of Ophthalmology continues to refine treatment protocols, with the ultimate goal of preserving vision and improving quality of life for individuals living with this challenging disease. For further reading on clinical trial data, the DRCR Retina Network publications and resources from the American Diabetes Association provide valuable updates on evolving standards of care. Additionally, comprehensive reviews of dual therapy approaches are available through the National Library of Medicine for clinicians seeking deeper insights into mechanistic and clinical considerations.